Fig 3.

Change in lesion burden from baseline (A) for all lesions, (B) injected lesions, (C) uninjected nonvisceral lesions, and (D) visceral lesions. Per protocol, visceral lesions were not injected. Evaluable patients had baseline and at least one postbaseline evaluation of lesion burden. In panel D, two patients identified as having stage IVM1a disease at baseline had visceral index lesions (one with an adrenal lesion and one with a lung lesion; indicated with (*) and (†), respectively). The remaining patients with stages IIIC and IVM1a disease developed visceral lesions during the study.